Home › Cancro al seno › Texas
Studi clinici su Cancro al seno nello stato di Texas
178 studi su Cancro al seno cercano partecipanti presso sedi nello stato di Texas.
Città nello stato di Texas
- Houston126 studi
- Dallas55 studi
- San Antonio46 studi
- Austin18 studi
- League City12 studi
- Fort Worth11 studi
- The Woodlands10 studi
- Sugar Land7 studi
- Irving6 studi
- Lubbock6 studi
- Tyler6 studi
- El Paso6 studi
- Abilene5 studi
- Lewisville5 studi
- Killeen4 studi
- McAllen4 studi
- Arlington3 studi
- Baytown3 studi
- Cypress3 studi
- Allen3 studi
- Denton3 studi
- Amarillo3 studi
Testo ufficiale dello studio (inglese)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- New Experimental Therapeutics - NEXT Oncology, Austin
- Texas Oncology, Bedford
- UT Southwest Simmons Cancer Center, Dallas
- e altri 2
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- El Paso Texas Oncology, El Paso
- Kelsey Seybold Clinic, Houston
- University of Texas, Houston
- e altri 2
In reclutamentoFase 3
Età da 18 a 100 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05827081A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Research Site, Houston
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07205822Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance Measurements
- UT MD Anderson Cancer Center, Houston
In reclutamentoStudio osservazionale
Età 18 e oltre · Donne · Aggiornato il 2 ott 2026 · NCT07855627A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06760819A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06172478A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- University of Texas Southwestern, Dallas
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07701941A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Texas Oncology DFW, Dallas
- The University of Texas Southwestern Medical Center, Dallas
- Texas Oncology Gulf Coast, Houston
- e altri 1
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07102381Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- e altri 1
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06625775A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Texas Oncology, Dallas
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06369285Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06324357Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- NEXT Houston, Galveston
- NEXT Oncology - PARENT, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07360314A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Houston
- Research Site, Round Rock
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT05877599A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- NEXT Dallas, Irving
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07578571BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- The University of Texas Md Anderson Cancer Center, Houston
- Next Oncology Dallas, Irving
- Next Oncology, San Antonio
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT06120283IKS014 in Advanced Solid Tumors That Express HER2
- START Dallas - Fort Worth, Fort Worth
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05872295Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Dallas
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05867251A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Texas Oncology - DFW ( Site 8003), Dallas
- JPS Health Network ( Site 0067), Fort Worth
- Texas Oncology - Gulf Coast ( Site 8006), Houston
- e altri 3
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07060807An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- Next Oncology Austin, Austin
- The University of Texas Md Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07222267Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- M D Anderson Cancer Center, Houston
In reclutamento
Età 30 e oltre · Donne · Aggiornato il 25 set 2026 · NCT02945579Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
- M D Anderson Cancer Center, Houston
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05766891A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Hendrick Medical Center ( Site 0009), Abilene
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
- e altri 7
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Texas Oncology-Dallas Presbyterian Hospital ( Site 8000), Dallas
- Parkland Health and Hospital System ( Site 0069), Dallas
- UT Southwestern Medical Center ( Site 0050), Dallas
- e altri 3
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06312176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Dallas
- Research Site, El Paso
- Research Site, Sugar Land
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06103864Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer
- The University of Texas M. D. Anderson Cancer Center, Houston
In reclutamento
Età 18 e oltre · Donne · Aggiornato il 25 set 2026 · NCT07179809ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- University of Texas Southwestern Medical Center, Dallas
- Houston Methodist Cancer Center, Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07007559TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
- Houston Methodist Hospital, Houston
In reclutamentoFase 1
Età da 18 a 80 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06251544A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- NEXT Oncology - Irving, Irving
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Dallas
- Clinical Trial Site, Dallas
- Clinical Trial Site, Denton
- e altri 3
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Houston Methodist Hospital, Houston
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07214532A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Hendrick Medical Center, Abilene
- World Research Link, Baytown
- Parkland Health and Hospital System, Dallas
- e altri 10
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174336ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
- University of Texas Southwestern Medical Center, Dallas
- Baylor College of Medicine, Houston
- MD Anderson Cancer Clinic - Mays Clinic, Houston
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06085833A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07114601A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Texas MD Anderson Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Oncology Consultants P.A., Houston
- e altri 1
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 22 set 2026 · NCT07287098A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213791A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
- South Texas Accelerated Research Therapeutics, LLC (START), San Antonio
In reclutamentoFase 1
Età 18 e oltre · Donne · Aggiornato il 21 set 2026 · NCT07524855A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Renovatio Clinical - El Paso, El Paso
- JPS Health Network, Fort Worth
- Renovatio Clinical, The Woodlands
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT05894239Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Baylor College of Medicine, Houston
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT07340541Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- M D Anderson Cancer Center, Houston
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT04038619Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.